Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2018

Aug 14, 2018

SELL
$46.25 - $104.45 $136,391 - $308,023
-2,949 Closed
0 $0
Q1 2018

May 15, 2018

SELL
$57.4 - $108.44 $80,589 - $152,249
-1,404 Reduced 32.25%
2,949 $313,000
Q4 2017

Feb 27, 2019

SELL
$23.02 - $60.5 $1,289 - $3,388
-56 Reduced 1.27%
4,353 $263,000
Q4 2017

Nov 21, 2018

BUY
$23.02 - $60.5 $1,289 - $3,388
56 Added 1.29%
4,409 $263,000
Q4 2017

Feb 14, 2018

BUY
$23.02 - $60.5 $100,206 - $263,356
4,353
4,353 $259,000

Others Institutions Holding NKTR

About NEKTAR THERAPEUTICS


  • Ticker NKTR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,404,992
  • Market Cap $178M
  • Description
  • Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in areas of unmet medical need in the United States and internationally. The company's products include Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist, which is in phase 3 clinical trial to treat metastatic melanoma, re...
More about NKTR
Track This Portfolio

Track Ibex Investors LLC Portfolio

Follow Ibex Investors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ibex Investors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Ibex Investors LLC with notifications on news.